跳至主要内容
临床试验/NCT00095758
NCT00095758已完成3 期

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Otsuka Pharmaceutical Development & Commercialization, Inc.28 个研究点 分布在 1 个国家目标入组 1,151 人开始时间: 2004年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
1,151
试验地点
28
主要终点
Change in a depression rating scale at endpoint

研究概览

简要总结

This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women, 18-65 years old
  • Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks in duration.
  • Treatment history of an inadequate response to at least one and no more than three antidepressants.

排除标准

  • 未提供

研究组 & 干预措施

A1

Placebo Comparator

干预措施: Antidepressant + Placebo (Drug)

A2

Active Comparator

干预措施: Antidepressant + Aripiprazole (Drug)

结局指标

主要结局

Change in a depression rating scale at endpoint

Change in a depression rating scale at endpoint

时间窗: Baseline, Week 8

次要结局

  • Change in a disability scale and Clinical Global Impression scale at endpoint
  • Change in a disability scale and Clinical Global Impression scale at endpoint(Baseline, Week 8)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (28)

Loading locations...

相似试验